EWSR1 and Ewing sarcoma: In summary, current levels of evidence strongly suggest that among the greater than 90% of ES tumors that harbor EWSR1 rearrangements, fusion type is no longer a reliable prognostic marker and should not be used to stratify therapy or instruct treatment decisions.